Advertisement

Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy

  • Laura Pérez-CarbonellEmail author
Sleep Disorders (A Iranzo, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Sleep Disorders

Abstract

Purpose of review

The aim of this review is to discuss and summarize the main therapeutic strategies for the management of excessive daytime sleepiness (EDS) in patients with narcolepsy. An overview of novel therapies and potential future options are covered as well.

Recent findings

First line treatments for EDS in narcolepsy patients include modafinil/armodafinil and sodium oxybate. Other options with a stimulant effect, such as methylphenidate and amphetamines are considered if the former do not control the symptoms. More recently, pitolisant (H3 receptor inverse agonist) was approved by the European Medicines Agency, and solriamfetol (dopamine and norepinephrine reuptake inhibitor) by the Food and Drug Administration, for the treatment of EDS in adult narcolepsy patients. Sodium oxybate was recently approved for EDS management in paediatric patients from the age of seven. Further studies involving the paediatric population are warranted to have solid evidence in the management of children with narcolepsy. Ongoing research of new molecules is based on several mechanisms of action (histamine antagonists/inverse agonists, GABA receptor modulators), and potential future strategies involve immunologic treatment and hypocretin-based therapies.

Summary

Additionally to the wakefulness-promoting agents and stimulants classically used, other pharmacologic options have been recently approved for the treatment of EDS in Europe (pitolisant) and the US (solriamfetol). Emerging treatments are under development; newly developed wakefulness-promoting agents act via different mechanisms of action, whereas other forms of therapy are focused in the underlying hypocretin deficiency that characterizes narcolepsy type 1.

Keywords

Narcolepsy Excessive daytime sleepiness Hypersomnolence Stimulant Wakefulness-promoting agent 

Notes

Compliance with Ethical Standards

Conflict of Interest

Laura Pérez-Carbonell declares no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654–62.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.•
    American Academy of Sleep Medicine. Systematic and imperious classification for the diagnosis of sleep disorders in its latest edition. In: International classification of sleep disorders. 3rd edition. In: diagnostic and coding manual. Westchester, IL: American Academy of Sleep Medicine; 2014. Systematic and imperious classification for the diagnosis of sleep disorders in its latest edition.Google Scholar
  3. 3.
    Andlauer O, Moore H 4th, Hong SC, et al. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep. 2012;35:1247–55F.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Barateau L, Lopez R, Dauvilliers Y. Treatment options for narcolepsy. CNS Drugs. 2016;30(5):369–79.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Dauvilliers Y, Barateau L. Narcolepsy and other central Hypersomnias. Continuum (Minneap Minn. 2017;23(4, Sleep Neurology):989–1004.Google Scholar
  6. 6.•
    Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 2015;16(1):9–18 Comprehensive and practical review of available treatments in narcolepsy.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Thakrar C, Patel K, D'ancona G, Kent BD, Nesbitt A, Selsick H, et al. Effectiveness and side-effect profile of stimulant therapy as monotherapy and in combination in the central hypersomnias in clinical practice. J Sleep Res. 2018;27(4):e12627.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Schwartz JR. Modafinil in the treatment of excessive sleepiness. Drug Des Devel Ther. 2009;2:71–85.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Billiard M, Besset A, Montplaisir J, Laffont F, Goldenberg F, Weill JS, et al. Modafinil: a double-blind multicentric study. Sleep. 1994;17(8 Suppl):S107–12.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Broughton RJ, Fleming JA, George CF, Hill JD, Kryger MH, Moldofsky H, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49(2):444–51.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol. 1998;43(1):88–97.CrossRefGoogle Scholar
  12. 12.
    Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology. 2000;54(5):1166–75.CrossRefGoogle Scholar
  13. 13.
    Darwish M, Kirby M, Hellriegel ET, Robertson P Jr. Armodafinil and modafinil have substantially different pharmacokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies. Clin Drug Investig. 2009;29(9):613–23.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    US Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25(1):42–9.Google Scholar
  15. 15.
    US Xyrem Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003;26(1):31–5.Google Scholar
  16. 16.
    Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep. 2004;27(7):1327–34.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005;1(4):391–7.Google Scholar
  18. 18.
    Boscolo-Berto R, Viel G, Montagnese S, Raduazzo DI, Ferrara SD, Dauvilliers Y. Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2012;16(5):431–43.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29(7):939–46.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz NL. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med. 2009;5(4):365–71. Review.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Mitler MM, Shafor R, Hajdukovich R, Timms RM, Browman CP. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep. 1986;9(1 Pt 2):260–4.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Billiard M, Bassetti C, Dauvilliers Y, Dolenc-Groselj L, Lammers GJ, Mayer G, et al. EFNS task force. EFNS guidelines on management of narcolepsy. Eur J Neurol. 2006;13(10):1035–48.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Barateau L, Lopez R, Dauvilliers Y. Management of Narcolepsy. Curr Treat Options Neurol. 2016;18(10):43.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Shindler J, Schachter M, Brincat S, Parkes JD. Amphetamine, mazindol, and fencamfamin in narcolepsy. Br Med J (Clin Res Ed). 1985 Apr 20;290(6476):1167–70.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Mitler MM, Hajdukovic R, Erman M, Koziol JA. Narcolepsy. J Clin Neurophysiol. 1990;7(1):93–118.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Mitler MM, Hajdukovic R, Erman MK. Treatment of narcolepsy with methamphetamine. Sleep. 1993;16(4):306–17.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Barateau L, Jaussent I, Lopez R, Boutrel B, Leu-Semenescu S, Arnulf I, et al. Smoking, alcohol, drug use, abuse and dependence in narcolepsy and idiopathic hypersomnia: a case-control study. Sleep. 2016 Mar 1;39(3):573–80.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Syed YY. Pitolisant: first global approval. Drugs. 2016;76(13):1313–8.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.•
    Dauvilliers Y, Bassetti C, Lammers GJ, et al.; HARMONY I study group. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068–75. Pivotal study demonstrating efficacy and safety of pitolisant for the treatment of daytime sleepiness in adult patients with narcolepsy.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Kollb-Sielecka M, Demolis P, Emmerich J, Markey G, Salmonson T, Haas M. The European medicines agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for human use. Sleep Med. 2017;33:125–9.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(3):200–7.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
  33. 33.
    •• Szabo ST, Thorpy MJ, Mayer G, Peever JH, Kilduff TS. Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy. Sleep Med Rev. 2019;43:23–36 Excellent review of underlying pathophysiological mechanisms of narcolepsy and potential therapeutic targets.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Bogan RK, Feldman N, Emsellem HA, Rosenberg R, Lu Y, Bream G, et al. Effect of oral JZP-110(ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015;16(9):1102–8.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Ruoff C, Swick TJ, Doekel R, Emsellem HA, Feldman NT, Rosenberg R, et al. Effect of Oral JZP-110(ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study. Sleep. 2016;39(7):1379–87.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.••
    Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359–70. Recent study demonstrating efficacy and safety of this novel treatment in the management of daytime sleepiness in adult patients with narcolepsy.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
  38. 38.
    Nittur N, Konofal E, Dauvilliers Y, Franco P, Leu-Semenescu S, Cock VCD, et al. Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. Sleep Med. 2013;14(1):30–6.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Mayer G, Ewert Meier K, Hephata K. Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol. 1995;18(4):306–19.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Trotti LM, Saini P, Koola C, LaBarbera V, Bliwise DL, Rye DB. Flumazenil for the treatment of refractory Hypersomnolence: clinical experience with 153 patients. J Clin Sleep Med. 2016;12(10):1389–94.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Trotti LM, Saini P, Bliwise DL, Freeman AA, Jenkins A, Rye DB. Clarithromycin in γ-aminobutyric acid-related hypersomnolence: a randomized, crossover trial. Ann Neurol. 2015;78(3):454–65.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Rogers AE, Aldrich MS, Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep. 2001;24(4):385–91.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Marín Agudelo HA, Jiménez Correa U, Carlos Sierra J, Pandi-Perumal SR, Schenck CH. Cognitive behavioral treatment for narcolepsy: can it complement pharmacotherapy? Sleep Sci. 2014;7(1):30–42.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, et al. Standards of practice Committee of the American Academy of sleep medicine. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705–11. Review.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Nevsimalova S. The diagnosis and treatment of pediatric narcolepsy. Curr Neurol Neurosci Rep. 2014;14(8):469.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Wise MS. Childhood narcolepsy. Neurology. 1998 Feb;50(2 Suppl 1):S37–42. Review.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Postiglione E, Antelmi E, Pizza F, Lecendreux M, Dauvilliers Y, Plazzi G. The clinical spectrum of childhood narcolepsy. Sleep Med Rev. 2018;38:70–85.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Lecendreux M. Pharmacological management of narcolepsy and cataplexy in pediatric patients. Paediatr Drugs. 2014;16(5):363–72.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Lecendreux M, Bruni O, Franco P, Gringras P, Konofal E, Nevsimalova S, et al. Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy. J Sleep Res. 2012;21(4):481–3.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness. NCT00214968. 2005. Available from: https://clinicaltrials.gov/ [Last accessed 28 July 2019].
  51. 51.••
    Plazzi G, Ruoff C, Lecendreux M, Dauvilliers Y, Rosen CL, Black J, et al. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation. Lancet Child Adolesc Health. 2018;2(7):483–94. Recent study that has confirmed the efficacy and safety of sodium oxybate in paediatric patients with narcolepsy from the age of seven.CrossRefGoogle Scholar
  52. 52.
    Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period. NCT02611687. 2015. Available from: https://clinicaltrials.gov/ [Last accessed 29 July 2019].
  53. 53.
    Thorpy M, Zhao CG, Dauvilliers Y. Management of narcolepsy during pregnancy. Sleep Med. 2013;14(4):367–76.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017;9:39–57.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Phase II randomized, double-blind, double-dummy, placebo and comparator-controlled, parallel group, multi-center study to investigate the safety and efficacy of a single dose of JNJ-17216498 administered to subjects with narcolepsy. NCT00424931. 2014. Available from: https://clinicaltrials.gov/ [Last accessed 28 July 2019].
  56. 56.
    A randomized, placebo-controlled, double-blind, fixed-dose, multiple cohort, multiple crossover, dose-finding study of oral BTD-001 in adults with idiopathic hypersomnia (IH) or Narcolepsy type 2. NCT02512588. 2017. Available from: https://clinicaltrials.gov/ [Last accessed 28 July 2019].
  57. 57.
    Huang YS, Guilleminault C. Narcolepsy: action of two γ-aminobutyric acid type B agonists, baclofen and sodium oxybate. Pediatr Neurol. 2009;41(1):9–16.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Black SW, Morairty SR, Chen TM. At al. GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy. J Neurosci. 2014;34(19):6485–94.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    The effect of caffeine on the narcoleptic patients randomized controlled clinical trial. NCT02832336. 2016. Available from: https://clinicaltrials.gov/ [Last accessed 28 July 2019].
  60. 60.
    Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy. NCT02720744. 2016. Available from: https://clinicaltrials.gov/ [Last accessed 28 July 2019].
  61. 61.
    Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients. NCT02821715. 2017. Available from: https://clinicaltrials.gov/ [Last accessed 28 July 2019].
  62. 62.
    Takenoshita S, Sakai N, Chiba Y, Matsumura M, Yamaguchi M, Nishino S. An overview of hypocretin based therapy in narcolepsy. Expert Opin Investig Drugs. 2018;27(4):389–406.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Nepovimova E, Janockova J, Misik J, Kubik S, Stuchlik A, Vales K, et al. Orexin supplementation in narcolepsy treatment: a review. Med Res Rev. 2019;39(3):961–75.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Bhattarai J, Sumerall S. Current and future treatment options for narcolepsy: a review. Sleep Sci. 2017;10(1):19–27.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019
corrected publication 2019

Authors and Affiliations

  1. 1.Sleep Disorders CentreGuy’s and St Thomas’ NHS Foundation TrustLondonUK

Personalised recommendations